Blood Coagulation Flashcards

1
Q

What are the main constituents of coagulation?

A
  • Vessel wall lined by endothelium.
  • Platelets - derived from megakaryocytes in marrow.
  • Coagulation factors in un-activated state.
  • Inhibitors of coagulation.
  • Fibrinolytic system and inhibitors.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are coagulation factors?

A
  • Coagulation factors = proteins which circulate in an inactive state and become activated in a cascade reaction and cause clotting.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Describe the role of endothelial cells.

A
  • Line blood vessels and form a barrier.
  • Produce thrombomodulin and heparin sulphate to inhibit thrombin production.
  • Enzymes to degrade platelet granule-derived molecules.
  • Prostacyclin and nitric oxide (NO) to reduce platelet adhesion.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe platelets.

A
  • Fragments of megakaryocyte cytoplasm.
  • Budded off into lumen of marrow sinusoids.
  • Production stimulated by thrombopoietin (TPO) - liver derived.
  • Cicrulate for 5-10 days with ~30% ‘stored’ in spleen.
  • Form a plug when attracted by lowered prostacyclin and by collagen exposure.
  • Thromboxane A2 and serotonin from platelets cause vasoconstriction.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How do platelets adhere to the vessel wall?

A

Platelets adhere to the vessel wall via Von Willibrand’s factor and Glycoprotein Ib.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How do platelets adhere to each other?

A

Platelets adhere to each other via glycoprotein IIb-IIIa and fibrinogen.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the functions of platelets?

A
  • Form a plug when attracted by lowered prostacyclin and by collagen exposure.
  • Granule release.
  • Fibrin formation.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe what happens in the coagulation cascade.

A
  • Factors present in inactive state - activated by ‘intrinsic or extrinsic’ pathway.
  • Fibrin is needed to form a clot.
  • Diagram:
    • Black = accelerator
    • Red = brakes (these try to prevent the coagulation cascade)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

List the factors which inhibit coagulation.

A
  • Protein C activated by thrombomodulin-thrombin complex.
  • With co-factor - factor S - Va and VIIIa are degraded.
  • Antithrombin (previously antithrombin III) inhibit Xa and IIa.
  • Heparin cofactor II inhibits IIa.
  • Heparin stimulated antithrombin and heparin cofactor II.
  • Only a very small amount of coagulation factor is needed; its effects build faster and faster. Results in coagulation happening faster than it can be inhibited.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Describe the fibrinolytic system.

A
  • Plasminogen activated to plasmin by tissue plasminogen activator (tPA) - from endothelial cells.
  • Fibrin broken down into ‘fibrin degradation products’ including D dimers - a measurement of fibrinolysis (a measure of how well a clot has broken down).
  • Inhibitors of fibrinolytic system.
  • Theraputic use with eg. streptokinase to tPA for ‘clot busting’ eg acute myocardial infarction or thrombotic stroke.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is fibrin?

A

Fibrin = meshwork of protein that can be brokwn down into its constituent parts.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the ‘gold-standard’ time frame for thrombolysis in stroke treatment?

A

Gold standard for stroke treatment - ideally in under 3 hours.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is clot retrieval?

A
  • Clot retrieval - putting a cathater in to pull the clot out.
  • Arguably more effective than dissolving the clot.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How do you measure coagulation?

A
  • Full blood count - includes platelet count / size / granules, but is a poor assessment of platelet function - specialised tests of aggregation can be done.
  • Ref range 150-400 x109 /L
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is caused by an FBC <30-50 x109/L?

And <10 x109/L?

A
  • Easy bruising and purpura when FBC <30-50 x109 /L (thrombocytopaenia).
  • Risk of major bleeding if <10 x109/L.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe a bleeding time test.

A
  • In vivo test of overall clotting - mainly platelet function.
  • Lots of poorly controlled variables, so not often done.
17
Q

Describe a prothrombin time (PT) test.

A
  • All coagulation tests are done on citrated plasma
    • Removes Ca2+
  • At 37℃, thromboplastin and Ca2+ are added.
  • Measure time until clot forms - extrinsic and common pathway.
  • Prolonged by low levels of II, X and VII.
18
Q

Describe an activated partial thromboplastin test (APTT).

A
  • Ca2+ kaolin and phospholipids added to citrated plasma.
  • Measure of intrinsic and common pathway.
  • Prolonged in haemophilia and by heparin.
19
Q

What is fibrinogen?

How is it measured?

A
  • Fibrinogen is the final substrate for making fibrin.
  • It can be measured by:
    • Clot density
    • Thrombin time - thrombin and Ca2+ added to citrated plasma
20
Q

Describe the further tests which can be carried out on prolonged PT or APTT.

A
  • Correction tests and factor assays
  • A prolonged PT or APTT can be tested further:
    • 50:50 mix with normal plasma to see if the prolongation corrects.
    • Factor assays to look for specific deficiencies.
21
Q

Describe the genetic causes of haemophilia A and B?

A
  • Haemophilia A and B:
    • X-linked defect in VIII or IX gene.
  • Commonly a new mutation so no family history.
  • Female heterozygotes (carriers) are not affected.
22
Q

What is the prevalence of Haemophilia A&B?

A

~1:5000 males

23
Q

Describe the variation in severity of haemophilia A&B.

A
  • Can be very mild - chance finding or issue for surgery.
  • Severe (<1% VIII level) - frequent bleeds into joints and soft tissues.
24
Q

Describe Von Willebrand disease.

A
  • Usually autosomal dominant.
  • Defect in platelet adhesion and binding of VIII.
  • Up to 1% population.
  • Mild disease - easy bruisingm heavy periods.
  • Severe disease - similar to haemophilia.
25
Q

Describe acquired coagulation disease of the liver.

A
  • Liver disease - alcohol / autoimmune / hepatitis.
    • All coagulation factors are produced in the liver.
    • PT and fibrinogen abnormal, later APPT abnormal.
    • Bleeding due to abnormal clotting, low platelets.
    • Portal hypertension causing oesophageal varices and upper GI bleeding.
26
Q

Describe acquired coagulation disease - disseminated intra-vascular coagulation (DIC).

How do you treat it?

A
  • Activation of clotting cascade due to:
    • Trauma
    • Malignancy eg. prostate cancer
    • Sepsis
    • Amniotic fluid embolism
  • Causes depletion of clotting factors and damage due to the clot.
  • Treat the cause and replace the clotting factors.
27
Q

What is thrombocytopaenia?

A

Low platelets

28
Q

What could thrombocytopaenia be due to?

A
  • Could be due to:
    • Under-production
    • Increased use
    • Abnormal distribution
29
Q

Describe thrombocytopaenia due to under production of platelets.

A
  • Abnormal marrow function - acute leukaemia, metastatic tumour, aplastic anaemia.
  • Expected side effect of cytotoxic chemotherapy.
  • Idiosyncratic and unexpected drug adverse effect eg. co-trimoxazole, anti-inflammatories.
30
Q

Describe thrombocytopaenia due to increased use.

A
  • Immune thrombocytopaenia (ITP)
    • Autoimmune disease of children or adults.
    • May be triggered by infection or drug.
    • Auto antibodies to platelets.
    • Treated by:
      • Watch and wait
      • Steroids
      • Immunoglobulins
      • Splenectomy
      • Drugs to mimic thrombopoetin
31
Q

Describe thrombocytopaenia due to abnormal distribution.

A
  • Splenomegally (abnormal enlargement of the spleen).
    • Examples:
      • Portal hypertension
      • Leukaemia
  • Can have large haemangioma.
32
Q

Describe thrombophilia

A
  • Increased risk of clotting.
  • Caused by:
    • Inherited defects in coagulation inhibitors, eg. protein C, S, antithrombin.
    • Inherited defect in factor V - Factor V Leiden (causes increased clotting).
    • Acquired problems - Virchow’s triad:
      • Abnormal vessel wall
      • Abnormal flow
      • Abnormal blood component
33
Q

What can cause an abnormal vessel wall?

A
  • Atheroma and plaque
  • Varicose veins
  • Aneurysm
34
Q

What can cause abnormal flow through a vessel?

A
  • Atrial fibrilation
  • Immobility (eg. long distance flight, plaster cast, surgery)
  • Varicose veins
35
Q

What can cause an abnormal blood component?

A
  • Increased haemoglobin / red cell count - polycythaemia.
  • Increased WBC or platelet count - stasis and increased clotting.
  • Increased viscosity of plasma.
  • Reduced coagulation factor inhibitors.
36
Q

What is polycythaemia?

A

An abnormally increased concentration of Hb in the blood, either through reduction of plasma volume or increased red cell numbers.